×
Program Committee
-
Jun Yamakami, PhD Senior Regulatory Expert, Regulatory Affairs Department Regulatory Consulting
A2 Healthcare Corporation, Japan -
Kazuishi Sekino, MS Director of MID-NET operation and management, Office of Medical Informatics and
Pharmaceuticals and Medical Devices Agency, Japan -
Satoko Utsunomiya Regulatory Affairs Area, Japan Development
MSD K.K., Japan -
Yuko Hata Associate director, Therapeutic Area Regulatory, Japan Regulatory Affairs
Takeda Pharmaceutical Company, Japan -
Toshinori Higashi, PhD Vice President, Regulatory Science
KAKEN PHARMACEUTICAL CO.,LTD., Japan -
Akifumi Kamata, PhD Office of New Drug I
Pharmaceuticals and Medical Devices Agency, Japan -
Miyuki Kaneko Japan Regulatory Portfolio Lead, Regulatory Affairs
Pfizer R&D Japan G.K., Japan -
Yukiko Kato Reviewer, Office of New Drug I
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Tsuyoshi Kobayashi Associate Director, Japan Regulatory Affairs
Eisai Co., Ltd., Japan -
Yasutsugu Nakano Senior Director, Regulatory Affairs Department
Shionogi & Co., Ltd., Japan -
Ryutaro Ochiishi New Drug Regulatory Affairs Department
Daiichi Sankyo, Japan -
Maiko Ono Associate Manager,New Drug Regulatory Affairs
GlaxoSmithKline K.K., Japan -
Toshiki Sugita, PhD Office of Review Management, Review Management Division
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Emiko Takezawa, MPharm, RPh Regulatory Science
ELIQUENT Japan, Inc., Japan -
Masayoshi Tanaka
Swedish Orphan Biovitrum Japan (Sobi Japan), Japan -
Shunsuke Tominaga, MPharm, RPh Head, RA Neauroscience, Gene Therapeutics and Medical Devices, Precision Medicin
Novartis Pharma K.K., Japan -
Hana Sugai
Pharmaceuticals and Medical Devices Agency (PMDA), Japan -
Satomi Yagi Reviewer, Office of New Drug III
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Have an account?